• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • MEI Pharma Announces Expansion of Zandelisib Phase 1b Study americanpharmaceuticalreview
    January 11, 2021
    MEI Pharma announced that the Phase 1b trial arm exploring zandelisib, an investigational selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, in combination with zanubrutinib (marketed as BRUKINSA®) ...

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service